Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow KAPA by emailGet an email when KAPA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KAPA, unsubscribe in one click. Privacy
📣 What KAPA Says Is Next
in 2026 · “CL-741 is a Phase 1-ready therapeutic candidate targeting EGFR-mutated lung cancer, a treatment landscape valued at an estimated $16.2B in 2026 ( Future Market Insights ).”
Company press release, Jun 4, 2026 · SEC filing
in 2026 · “The program is currently pre-IND, with first-in-human clinical trials projected to commence in 2026.”
Company press release, Feb 26, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full KAPA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KAPA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.